Achieve Life Sciences (ACHV) vs Celldex Therapeutics (CLDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 118.1% versus a gain of 16.1%. Over five years, ACHV leads with a -10.1% price change compared with -34.1% for CLDX. Celldex Therapeutics is the larger company by market cap ($2.39 billion vs $746.5 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | CLDX |
|---|---|---|
| Share price | $7.24 | $30.43 |
| Market cap | $746.46M | $2.39B |
| 1-day change | +2.99% | -1.85% |
| YTD return | +45.67% | +12.04% |
| 1-year return | +118.07% | +16.06% |
| 5-year return | -10.06% | -34.11% |
| EPS (TTM) | $-1.69 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.54M |
| Revenue growth (YoY) | — | -77.99% |
| Net income (latest FY) | — | $-258.76M |
| Gross margin | — | 87.06% |
| Operating margin | — | -18599.81% |
| Net margin | — | -16748.03% |
| 52-week high | $8.64 | $45.14 |
| 52-week low | $2.62 | $22.10 |
| Distance from 52-week high | -16.20% | -32.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +95.44% | +107.26% |
| Average volume | 1.45M | 1.26M |
| Shares outstanding | 103.10M | 78.53M |
| Employees | 28 | 198 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 3.2 times larger than Achieve Life Sciences by market value ($2.39B vs $746.46M).
- ACHV has outperformed CLDX by 102.0 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
ACHV vs CLDX FAQ
Which is bigger, Achieve Life Sciences or Celldex Therapeutics?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.39B compared with $746.46M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or CLDX?
ACHV returned +118.07% over the past 12 months, compared with +16.06% for CLDX (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Celldex Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.